What's Trending in Stocks Right Now

Cue Biopharma (CUE) reported positive topline results from a Phase 2 trial of CUE-221 in 145 patients with moderate to severe chronic spontaneous urticaria inadequately controlled on H1 antihistamines.

The randomized, double-blind study in China tested CUE-221 at 1, 2 and 4 mg/kg subcutaneously every 4 weeks versus placebo and omalizumab. The primary endpoint, complete resolution of hives (HSS7=0) at week 12, was dose‑responsive and met at all CUE-221 doses, with 54%, 53% and 43% responders for 4, 2 and 1 mg/kg versus 11% for placebo (p<0.005, p<0.005, p<0.05). The key secondary endpoint, complete response UAS7=0 at week 12, reached statistical significance at 4 mg/kg (46% vs 11% placebo, p<0.05). Complete hive resolution rates with CUE-221 peaked at week 22 and remained clinically meaningful up to week 28 at 4 mg/kg, including a post hoc statistically significant 36% delta versus omalizumab. CUE-221 showed a favorable safety profile with no treatment‑related serious adverse events or anaphylaxis.

Faraday Future (FFAI) launched nine new Embodied AI (EAI) device configurations and four Industry Productivity Solutions at its 919 FF EAI Robotics event, completing its “One-Brain Multi-Form Multi-Capability” FF EAI Robot World 2.0.

The new portfolio spans humanoid and quadruped robots across five series and 11 models, now totaling 24 products. Key launches include the FF All-New Futurist professional humanoid robot priced from $89,900, the compact FF Master Mini series starting at $9,990, the FX Aegis Hyper quadruped starting at $137,900, FX Aegis Mega from $74,990, and FX Aegis Classic Ultra-W at $12,990, each bundled with Skills Packages of stated values. The company reports an average contribution margin of about 30% on its robotics products based on Q2 results.

FF also introduced K-12 Education, Research, Security and Inspection solutions, and started sales and delivery through a new “6+1” direct sales and RoboShare rental network, with ordering via FF.com, Amazon and RobotShop.

Greenland Mines (GRML) welcomed a new security agreement among the United States, Denmark and Greenland that expands the U.S. security presence in Greenland and restricts military positions and sensitive investments by U.S. adversaries. The company said the deal highlights Greenland’s rising strategic importance for defense, technology and energy security.

Greenland Mines highlights two key assets: the Sarfartoq rare earths project, with an Initial Assessment high-case pre-tax NPV of about $2.05 billion, and the Skaergaard palladium-platinum-gold and vanadium mineral system. Planned annual NdPr oxide output from Sarfartoq would equal roughly 34% of all NdPr oxide currently refined outside China at 2025 consumption levels, supporting the company’s vision for a North Atlantic Critical Metals Corridor linking Greenland resources with allied downstream infrastructure.

Research Frontiers (REFR) announced that long-time licensee Gauzy has obtained final court approval for its comprehensive debt settlement and restructuring, following support from creditors representing 98.96% of voting claims, including 100% of its secured lenders.

The company said this outcome enables Gauzy to refocus resources on operations, customers and growth, and that activities and funding are already flowing to restart production of SPD light-control film in Germany and SPD emulsion in Israel. Restarting SPD production is described as critical for existing and next-generation SPD-SmartGlass programs across automotive, aircraft, marine and architectural markets, and for new initiatives such as black SPD film and large architectural retrofit products. Research Frontiers reiterated its focus on supporting licensees, expanding existing programs and bringing SPD-SmartGlass technology to additional products and markets worldwide.

BlossomHill Therapeutics (BLSM) reported second quarter 2026 results and pipeline progress on September 18, 2026.

The company strengthened its balance sheet with approximately $168.3 million in gross proceeds from its upsized August 2026 IPO, after ending June 30, 2026 with $95.4 million in cash and cash equivalents. BlossomHill expects existing cash plus IPO proceeds to fund operations into the second quarter of 2028. The FDA granted Fast Track designation to lead asset BH-30643 for advanced EGFR C797S-positive NSCLC. Phase 1 SOLARA data showed a 45% objective response rate and 88% disease control rate in patients with C797S resistance to prior TKIs.

R&D expenses rose to $21.4 million and G&A to $3.3 million, driving a quarterly net loss of $23.8 million, or $(8.75) per share.

Keysight (KEYS) will demonstrate end-to-end test and measurement solutions for high-speed optical and AI infrastructure at ECOC 2026 from September 21–23, 2026, at booth #1154 in FYCMA, Málaga, Spain.

Demonstrations will cover photonic design and characterization, AI infrastructure and interconnect validation, next-generation optical research, 1.6T optical validation and production test, and 3.2T optical research. Keysight experts plan to show workflows that link photonic simulation with automated PIC test and up to 220 GHz characterization, tools to validate 1.6T transmitters and receivers, and systems to benchmark AI fabric performance, emulate real-world workloads, and test AI transport and inference at scale. The company will also highlight AI-enabled test automation aimed at simplifying photonics test development, troubleshooting, and data analysis.

DataMeds AI (MEDS) has settled litigation tied to a May 11, 2023 purchase agreement, extinguishing about $19 million of balance-sheet liabilities.

Under the Settlement Agreement related to the Wellgistics, LLC Membership Purchase Interest Agreement, the company retired approximately 364,099 shares of its common stock and paid $450,000 in cash. The company said resolving this outstanding litigation will allow greater focus on its Health IT, pharmacy and telemedicine operations, which incorporate its EinsteinRx™ AI platform and PharmacyChain™ smart contracts technology. Additional details are available in a Form 8-K filed with the Securities and Exchange Commission.

Taboola (TBLA) has announced an offer to acquire Dianomi, a digital advertising provider focused on business, finance and lifestyle sectors, with completion expected before the end of 2026 subject to regulatory conditions and Dianomi shareholder approval.

Dianomi gives premium advertisers, including brands such as Charles Schwab, Invesco and Bank of America, access to large, high-intent audiences through partnerships with hundreds of premium publishers like Reuters, CNN Business, the Times and WSJ. More than 600 advertisers and publishers use Dianomi’s brand-safe environments to drive performance. Taboola expects the deal to significantly enhance its ability to serve performance advertisers with a specialized, finance-focused premium ad network, powered by its Realize performance advertising platform, which uses Taboola’s supply, first-party data and AI to run performance campaigns across major publishers.

Teva (TEVA) reported new post hoc and switching data for investigational once-monthly subcutaneous olanzapine LAI TEV-'749 from the Phase 3 SOLARIS program in adult schizophrenia.

In the long-term open-label stage, 231 of 411 participants (56%; 61%, 54% and 54% in the 318-, 425- and 531-mg groups) achieved stabilization. Among those stabilized, 10 of 231 (4%; 6%, 1% and 5%) relapsed, and 39 of 183 patients (21%; 26%, 13% and 26%) treated for at least six months met PANSS-based remission criteria. Pharmacokinetic simulations indicated that initiating TEV-'749 one day after the last oral or short-acting intramuscular olanzapine dose produced olanzapine exposure within established oral therapeutic ranges. Metabolic outcomes showed a profile consistent with daily oral olanzapine without a clear dose-dependent pattern.

TEV-'749 is not yet approved. An FDA PDUFA decision is expected in Q4 2026, and the EMA accepted the marketing application in May 2026.